Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Brain Tumor Center
This phase II clinical trial will evaluate Ad-RTS-hIL-12 in combination with veledimex and cemiplimab-rwlc for treating patients with recurrent glioblastoma.
